MedTrace Logo

Hypofractionated Radiotherapy for Recurrent DIPG

NCT03841435 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-09-13

No results posted yet for this study

Summary

This study evaluates the feasibility of hypofractionated radiotherapy (RT) in the palliative treatment of recurrent diffuse intrinsic pontine glioma (DIPG). Participants will receive 15 Gy in 3 fractions as opposed to the standard 20 Gy in 10 fractions.

Conditions

  • Recurrent Diffuse Intrinsic Pontine Glioma

Interventions

RADIATION

Hypofractionated Radiotherapy

Radiotherapy Treatment, totaling 15 Gy, will be given in 3 fractions over 2 weeks.

Sponsors & Collaborators

  • Children's Hospital Medical Center, Cincinnati

    collaborator OTHER

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Luke E Pater, MD · University of Cincinnati

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2023-03-03
Completion
2023-03-03

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03841435 on ClinicalTrials.gov